natgillin/translations-raw huggingface dataset:
Descovy leveres i flasker, der indeholder 30 tabletter (med et silicagel-tørremiddel, der skal opbevares i flasken for at hjælpe med at beskytte tabletterne).
Descovy comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets).
Descovy skal administreres som vist i tabel 1.
Descovy should be administered as shown in Table 1.
Desensibilisering kan opnås ved at begynde med 10 mg para-aminosalicylsyre som en enkelt dosis.
Desensitization can be accomplished by starting with 10 mg para-aminosalicylic acid given as a single dose.
Design: randomiseret (1:1), dobbeltblindet, placebokontrolleret.
Design: randomised (1:1), double-blinded, placebo-controlled.
Design: randomiseret globalt multicenter studie, ikke-blindet
Design: randomised, global multicentre, open-label
Design: randomiseret, globalt multicenter studie, dobbeltblindet, placebokontrolleret Behandling: Viekirax og dasabuvir med ribavirin baseret på vægt i 12 uger
Design: randomised, global multicentre, double-blind, placebo-controlled Treatment: Viekirax and dasabuvir with weight-based ribavirin for 12 weeks
Design: randomiseret, globalt multicenter studie, ikke-blindet
Design: randomised, global multicentre, open-label
Designet af dette studie muliggør ikke estimering af risikoen for MCI- progression til klinisk Alzheimers sygdom.
The design of this study does not allow estimating the risk of MCI progression to clinical AD.
Designet for undersøgelsen tager ikke hensyn
The design of the study does not allow for
Desinfektionsserviet
Alcohol swab
Desinficer cylinderampullens gummimembran med en renseserviet.
Disinfect the rubber membrane of the cartridge with a cleansing swab
Desinficer cylinderampullens gummimembran med en renseserviet.
With a cleansing swab, disinfect the rubber membrane of the cartridge.
Desinficer Deres hud med desinfektionsservietten, og hold om huden med Deres pege- og tommelfinger uden at klemme hårdt til.
Disinfect your skin by using the alcohol wipe and pinch the skin between your thumb and forefinger, without squeezing it.
Desinficer gummipropoen med sprit
Disinfect the rubber seal with alcohol.
Desinficer gummiproppen med sprit.
Disinfect the rubber seal with alcohol.
Desinficer huden med en afspritningsserviet.
Disinfect your skin by using an alcohol wipe.
Desinficer huden over crista iliaca superior.
Disinfect the skin above the supra-iliac crest.
Desinficer indsprøjtningsstedet med en spritserviet og tag godt fat i huden med tommel- og pegefingeren uden at klemme til (se figur 5).
Disinfect the injection site by using an alcohol swab and pinch the skin between your thumb and forefinger, without squeezing it (see picture 5).
Desinficer injektionsområdet på (over)låret med en spritserviet som vist på nedenstående billede.
Disinfect the injection area using the alcohol swab as pictured below at the (front) thigh.
desinficerende servietter eller lignende, og
alcohol wipes or similar; and
desinficerende servietter eller lignende.
alcohol wipes or similar.
Desinficerende servietter og andre artikler kan bortskaffes gennem dagrenovationen.
Antiseptic wipes and other supplies can be disposed of in your garbage.
Desinficér overfladen af propperne på begge glas vha. gaze dyppet i 70 % alkohol.
Disinfect the surface of the stoppers of both vials with a gauze soaked in 70 % alcohol.
desipramin, nortriptylin, paroxetin og lignende medicin (mod depression)
desipramine, nortriptyline, paroxetine and similar medicines (used to treat depression)
desipramin, trazodon og bupropion (medicin mod depression; bupropion anvendes også som rygeafvæningsmiddel)
desipramine, trazodone and bupropion (used to treat depression; bupropion is also used for smoking cessation)
Desirudin består af et enkeltkædet polypeptid af 65 aminosyrerester og 3 disulfid-bindinger.
Desirudin consists in a single chain polypeptide of 65 amino acid residues and 3 disulphide bridges.
Desirudin bør anvendes med forsigtighed til patienter, som får antikoagulantia, og/eller thrombocyt- hæmmere, og/eller non steroid antiinflammatoriske lægemidler.
Desirudin should be used with care in patients receiving anticoagulants, and/or platelet inhibitors, and/or non-steroidal anti-inflammatory medicinal products.
Desirudin bør anvendes med forsigtighed under omstændigheder med øget risiko for blødninger, som ved store operationer, biopsi eller punktur af et ikke kompressibelt blodkar indenfor de seneste måneder; tidligere tilfælde af hjerneblødning, intrakraniel eller intraokulær blødning inkl. diabetisk (hæmorragisk) retinopati: anfald af iltmangel til hjernen indenfor de senste 6 måneder, en kendt forstyrrelse af hæmostasen (medfødt eller akkvisit f.eks. hæmofili, leversygdom) eller tidligere tilfælde af gastrointestinal eller pulmonal blødning indenfor de seneste 3 måneder.
Desirudin should be used with caution in conditions with increased risks of haemorrhage such as major surgery, biopsy or puncture of a non-compressible vessel within the last month; a history of haemorrhagic stroke, intracranial or intraocular bleeding including diabetic (haemorrhagic) retinopathy; a cerebral ischaemic attack within the last 6 months, a known haemostatic disorder (congenital or acquired, e.g. haemophilia, liver disease) or a history of gastrointestinal or pulmonary bleeding within the past 3 months.
Desirudin bør ikke gives intramuskulært på grund af risiko for lokalt hæmatom.
Desirudin should not be administered by intramuscular injection owing to the risk of local haematoma.
Desirudin er kontraindiceret til patienter med:
Desirudin is contraindicated in patients:
Desirudin fremstilles ved hjælp af ’rekombinant DNA-teknologi’: Det produceres af en gærart, der har fået indsat et gen (DNA), som gør den i stand til at producere stoffet.
Desirudin is produced by a method known as ’recombinant DNA technology’: it is made by a yeast that has received a gene (DNA), which makes it able to produce the substance.
Desitin Pharma AS Niels Leuchs vei 99 1359 Eiksmarka Norge
Desitin Pharma AS Niels Leuchs vei 99 1359 Eiksmarka Norway
Desloratadin bindes moderat (83 %-87 %) til plasmaproteiner.
Desloratadine is moderately bound (83 % - 87 %) to plasma proteins.
Desloratadin er en ikke-sederende, langtidsvirkende histaminantagonist med selektiv perifer H1 receptorantagonist-aktivitet.
Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1- receptor antagonist activity.
Desloratadin er en ikke-sederende, langtidsvirkende histaminantagonist med selektiv perifer H1- receptorantagonist aktivitet.
Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1- receptor antagonist activity.
Desloratadin er en ikke-sederende, langtidsvirkende histaminantagonist med selektiv perifer H1- receptorantagonist aktivitet.
Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1-receptor antagonist activity.
Desloratadin og pseudoephedrinsulfat:
Desloratadine and Pseudoephedrine sulphate:
Desloratadin Teva 5 mg filmovertrukne tabletter er pakket i blisterpakninger med 7, 10, 14, 20, 21,
Desloratadine Teva 5 mg film-coated tablets are supplied in blister packs of 7, 10, 14, 20, 21, 28, 30, 40, 50,
Desloratadine Actavis 5 mg filmovertrukne tabletter
Desloratadine Actavis 5 mg film-coated tablets
Desloratadine Actavis 5 mg tablet desloratadin
Desloratadine Actavis 5 mg tablets desloratadine
Desloratadine Actavis desloratadin
Desloratadine Actavis desloratadine
Desloratadine Actavis er et ‘generisk lægemiddel’.
Desloratadine Actavis is a ‘generic medicine’.
Desloratadine Actavis er indiceret hos voksne og unge i alderen 12 år og derover til symptomlindring i forbindelse med:
Desloratadine Actavis is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
Desloratadine Actavis indeholder desloratadin, som er et antihistamin.
Desloratadine Actavis contains desloratadine which is an antihistamine.
Desloratadine ratiopharm 5 mg filmovertrukket tablet Desloratadin
Desloratadine ratiopharm 5 mg film-coated tablets Desloratadine
Desloratadine ratiopharm 5 mg filmovertrukne tabletter
Desloratadine ratiopharm 5 mg film-coated tablets
Desloratadine ratiopharm 5 mg filmovertrukne tabletter er indiceret hos voksne og unge i alderen 12 år og derover til symptomlindring i forbindelse med:
Desloratadine ratiopharm 5 mg film-coated tablets is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
Desloratadine ratiopharm desloratadin
Desloratadine ratiopharm desloratadine
Desloratadine ratiopharm er et ‘generisk lægemiddel’.
Desloratadine ratiopharm is a ‘generic medicine’.
Desloratadine ratiopharm indeholder desloratadin, som er et antihistamin.
Desloratadine ratiopharm contains desloratadine which is an antihistamine.
Desloratadine ratiopharm lindrer symptomer forbundet med allergisk snue (inflammation af næsepassager forårsaget af allergi, for eksempel høfeber eller støvmideallergi) hos voksne og unge i alderen 12 år og derover.
Desloratadine ratiopharm relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older.
Desloratadine Teva anvendes også til at lindre symptomerne i forbindelse med nældefeber (en hudlidelse forårsaget af allergi) hos voksne og unge i alderen 12 år og derover.
Desloratadine Teva is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy).
Desloratadine Teva er et ‘generisk lægemiddel’.
Desloratadine Teva is a ‘generic medicine’.
Desloratadine Teva er indiceret hos voksne og unge i alderen 12 år og derover til symptomlindring i forbindelse med:
Desloratadine Teva is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
Desloratadine Teva lindrer symptomer forbundet med allergisk snue (inflammation af næsepassager forårsaget af allergi, for eksempel høfeber eller støvmideallergi).
Desloratadine Teva relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older.
Deslorelin (som deslorelinacetat) 4,7 mg
Deslorelin (as deslorelin acetate) 4.7 mg
Deslorelin (som deslorelinacetat) 9,4 mg
Deslorelin (as deslorelin acetate) 9.4 mg
desmethyl-
Desmethyl
desmethyl-venlafaxin: 
desmethyl-venlafaxine: 
Desorientación (confusión) y mareo.
Disorientation (confusion) and dizziness
Desorientering
disorientation
desorientering
disorientation,
desorientering
feeling disorientated
desorientering, angst
feeling disorientated; anxiety
Desorientering, eufori
disorientation, euphoric mood
Desorientering, euforisk stemning
disorientation, euphoric mood
desorientering, hukommelsestab (amnesi)
disorientation, amnesia (loss of memory)
desorientering, hukommelsestab, svimmelhed, søvnighed, abnorme drømme
disorientation, amnesia (loss of memory), dizziness, somnolence (sleepiness), abnormal dream
Desorientering, nervøsitet, søvnløshed
Disorientation, feeling nervous, being unable to sleep
Desoxycorton pivalat 25 mg/ml
Desoxycortone pivalate 25 mg/ml
Destilleret vand
Purified water
Destruer den fyldte kanyleboks i henhold til lokale retningslinjer eller i følge vejledning fra din sundhedsperson.
Dispose of the full container according to local requirements or as instructed by your healthcare professional.
Destruer den fyldte kanyleboks i henhold til lokale retningslinjer eller i følge vejledning fra din sundhedsperson.
Dispose of the full container according to local requirements or as instructed by your healthcare provider.
Destruer Deres FORSTEO-pen og brugte nåle, som anvist af Deres læge, sygeplejerske eller apotekspersonalet.
Dispose of your FORSTEO and used needles as directed by your doctor or pharmacist.
Desuden afslørede en Single Photon Emission Computed Tomography (SPECT) studie af skizofrene patienter, at olanzapin- responderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidon-responderende patienter, hvorimod det var sammenligneligt med clozapin-responderende patienter.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Desuden afslørede en Single Photon Emission Computed Tomography (SPECT) undersøgelse af skizofrene patienter, at olanzapin- responderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidon-responderende patienter, hvorimod det var sammenligneligt med clozapin-responderende patienter.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Desuden afslørede en Single Photon Emission Computed Tomography (SPECT) undersøgelse af skizofrene patienter, at olanzapin-responderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidon-responderende patienter, hvorimod det var sammenligneligt med clozapin- responderende patienter.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Desuden afslørede en Single Photon Emission Computed Tomography (SPECT) undersøgelse af skizofrene patienter, at olanzapin-responderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidon-responderende patienter, hvorimod det var sammenligneligt med clozapin-responderende patienter.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine- responsive patients.
Desuden afslørede en Single Photon Emission Computed Tomography (SPECT) undersøgelse af skizofrene patienter, at olanzapin-responderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidon-responderende patienter, hvorimod det var sammenligneligt med clozapin-responderende patienter.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Desuden afslørede et Single Photon Emission Computed Tomography (SPECT) studie af skizofrene patienter, at olanzapin- responderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidon-responderende patienter, hvorimod det var sammenligneligt med clozapin-responderende patienter.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Desuden afslørede et Single Photon Emission Computed Tomography (SPECT) studie af skizofrene patienter, at olanzapin-responderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidon- responderende patienter, hvorimod det var sammenligneligt med clozapin-responderende patienter.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Desuden afslørede et Single Photon Emission Computed Tomography (SPECT) studie af skizofrene patienter, at olanzapin-responderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidon-responderende patienter, hvorimod det var sammenligneligt med clozapin-responderende patienter.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Desuden afslørede et Single Photon Emission Computed Tomography (SPECT) studie af skizofrene patienter, at olanzapinresponderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidon-responderende patienter, hvorimod det var sammenligneligt med clozapinresponderende patienter.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Desuden afslørede et Single Photon Emission Computed Tomography (SPECT) studie af skizofrene patienter, at olanzapinresponderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidonresponderende patienter, hvorimod det var sammenligneligt med clozapinresponderende patienter.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Desuden afslørerede et Single Photon Emission Computed Tomography (SPECT) studie af skizofrene patienter, at olanzapin-responderende patienter havde en lavere striatal D2-binding end visse andre antipsykotika- og risperidon- responderende patienter, hvorimod det var sammenligneligt med clozapin-responderende patienter.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Desuden aktiverer det immunsystemets celler, så de dræber kræftcellerne.
It also activates cells of the immune system, which then kill the cancer cells.
Desuden anbefales det, at HIV-inficerede kvinder ikke ammer deres spædbørn for at undgå at overføre HIV.
Additionally, it is recommended that HIV infected women do not breast feed their infants in order to avoid transmission of HIV.
Desuden anvendes det hos patienter, der har genmutationen T315I og derfor ikke reagerer på behandling med imatinib, dasatinib eller nilotinib.
It is also used in patients who have a genetic mutation called ‘T315I mutation’ which makes them resistant to treatment with imatinib, dasatinib or nilotinib.
Desuden anvendes det til Pagets sygdom (en knoglesygdom, der bevirker ændringer i knoglernes nedbrydning og genopbygning) og ved hyperkalcæmi (forhøjet calciumindhold i blodet) forårsaget af kræft.
It is also used in Paget’s disease (a bone disease that involves bone destruction and regrowth that causes deformity), and in hypercalcaemia (increased blood calcium) caused by cancer.
Desuden bekræftede DNA-sekventering af T-cellereceptorer, at T-cellernes klonalitet var øget ved behandling med daratumumab, hvilket tyder på immunmodulerende virkninger, som kan bidrage til klinisk respons.
In addition, T-cell receptor DNA sequencing verified that T-cell clonality was increased with daratumumab treatment, indicating immune modulatory effects that may contribute to clinical response.
Desuden bemærkede CHMP, at den overordnede gavnlige virkning af Pradaxa til behandling og forebyggelse af DVT og lungeemboli var sammenlignelig med virkningen af warfarin.
In addition, the CHMP noted that the overall benefit of Pradaxa in the treatment and prevention of DVT and PE is comparable to that of warfarin.
Desuden bemærkede ud- valget, at de fleste patienter foretrækker at inhalere et pulver frem for at bruge en nebulisator.
In addition, the Committee noted that patients generally prefer inhaling powder to using a nebuliser.
Desuden bemærkede udvalget, at fordelene ved Orkambi blev opretholdt i hele behandlingsvarigheden på 48 uger.
In addition the committee noted that the benefits of Orkambi were maintained for the duration of treatment of 48 weeks.
Desuden blev AUC for totalt aktivt rifabutin (moderstof + 25-O- desacetyl metabolit) forøget 1,6 gange, mens Cmax forblev sammenlignelig.
Furthermore, AUC of the sum of active moieties of rifabutin (parent drug + 25-O-desacetyl metabolite) was increased 1.6-fold, while Cmax remained comparable.
Desuden blev de bivirkninger, der er markeret med ** set i studiet med 204 patienter, der modtog Zevalin som konsolideringsbehandling efter 1. linje- remissionsinduktion, hvor det var indiceret.
In addition, the adverse drug reactions marked with ** were observed in the study with 204 patients receiving Zevalin as consolidation therapy after first-line remission induction where indicated.
Desuden blev der fremlagt undersøgelser fra den offentliggjorte litteratur af patienter med thalassaemia major til at underbygge anvendelsen af Ferriprox sammen med andre jernchelatdannende stoffer.
In addition, studies from the published literature in patients with thalassaemia major were provided to support use of Ferriprox in combination with another iron chelator.
Desuden blev der ikke observeret maligniteter hos 192 pædiatriske patienter med en eksponering på 498,1 patientår i Humira-studier med pædiatriske patienter med Crohns sygdom.
In addition, no malignancies were observed in 192 paediatric patients with an exposure of 498.1 patient years during Humira trials in paediatric patients with Crohn’s disease.
Desuden blev der ikke observeret nogen klinisk relevante arytmier under forsøget.
Additionally, no clinically relevant arrhythmias were observed during the conduct of the trial.
Desuden blev der indberettet 1 ikke-alvorlig forekomst af "vanskeligheder med tilpasning til lysforhold" (ikke afhjulpet) i ikke- interventionsstudiet INJECT.
Additionally, 1 non-serious case of ‘light adaptation difficulties’ (not resolved) was reported in the non-interventional study INJECT.
Desuden blev det i en prospektiv planlagt analyse vist, at injektion med Bondenza 3 mg hver 3. måned var bedre end oral ibandronsyre 2,5 mg daglig efter et år (p<0,001) og efter to år (p<0,001).
Furthermore, Bondenza 3 mg injection every 3 months was proven superior to oral ibandronic acid
Desuden blev det i en prospektiv planlagt analyse vist, at injektion med Bonviva 3 mg hver 3. måned var bedre end oral ibandronsyre 2,5 mg daglig efter et år (p<0,001) og efter to år (p<0,001).
Furthermore, Bonviva 3 mg injection every 3 months was proven superior to oral ibandronic acid
Desuden blev en farmakokinetisk-farmakodynamisk analyse (af virkning) udført i et studie af virkning ved primært generaliserede tonisk-kloniske anfald.
In addition, a pharmacokinetic-pharmacodynamic (efficacy) analysis was performed in one efficacy trial for primary generalised tonic clonic seizures.
Desuden blev et flertal af de patienter, der deltog i hovedundersøgelsen, fulgt op i 24 måneder.
In addition, a majority of patients who entered the main study were followed up for up to 24 months afterwards.